{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:08:48Z","timestamp":1772060928174,"version":"3.50.1"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5U01AI091429"],"award-info":[{"award-number":["5U01AI091429"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["L30 AI120170"],"award-info":[{"award-number":["L30 AI120170"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Rifamycins exhibit concentration-dependent killing of\n            <jats:named-content content-type=\"genus-species\">Mycobacterium tuberculosis<\/jats:named-content>\n            ; higher exposures potentially induce better outcomes. We randomized 180 tuberculosis patients in Peru to receive rifampin at 10, 15, or 20 mg\/kg\/day. A total of 168 had noncompartmental pharmacokinetic analyses; 67% were sampled twice, and 33% were sampled six times. The doses administered were well tolerated. The median area under the concentration-time curve from 0 to 6 h (interquartile range) was 24.9 (17.6 to 32.1), 43.1 (30.3 to 57.5), or 55.5 (35.7 to 73.2) h \u00b7 \u03bcg\/ml. The median maximum drug concentration in serum in the experimental arms reached the target of 8 \u03bcg\/ml. Continued investigation of higher rifampin doses is warranted. (This study has been registered at ClinicalTrials.gov under registration no. NCT01408914.)\n          <\/jats:p>","DOI":"10.1128\/aac.00038-17","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:40:34Z","timestamp":1496191234000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis"],"prefix":"10.1128","volume":"61","author":[{"given":"C. A.","family":"Peloquin","sequence":"first","affiliation":[{"name":"University of Florida College of Pharmacy and Emerging Pathogens Institute, Gainesville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-0692","authenticated-orcid":false,"given":"G. E.","family":"Vel\u00e1squez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lecca","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Socios En Salud, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. I.","family":"Calder\u00f3n","sequence":"additional","affiliation":[{"name":"Socios En Salud, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Coit","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Milstein","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Osso","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Socios En Salud, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Tintaya","sequence":"additional","affiliation":[{"name":"Socios En Salud, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sanchez Garavito","sequence":"additional","affiliation":[{"name":"Hospital Nacional Sergio Bernales, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Vargas Vasquez","sequence":"additional","affiliation":[{"name":"Hospital Nacional Hip\u00f3lito Unanue, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. D.","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Partners In Health, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Davies","sequence":"additional","affiliation":[{"name":"Institutes of Infection and Global Health and Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"3","article-title":"What is the \u201cright\u201d dose of rifampin?","volume":"7","author":"Peloquin C","year":"2003","unstructured":"Peloquin C . 2003. What is the \u201cright\u201d dose of rifampin?Int J Tuberc Lung Dis7:3\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560802694564"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.180"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1061LE"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1843OC"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1790-x"},{"key":"e_1_3_2_9_2","volume-title":"Treatment of tuberculosis guidelines","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. 2010. Treatment of tuberculosis guidelines, 4th ed. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/tb\/publications\/tb_treatmentguidelines\/en\/. (Accessed 22 November 2016.)","edition":"4"},{"key":"e_1_3_2_10_2","volume-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard","author":"Clinical and Laboratory Standards Institute","year":"2003","unstructured":"Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_11_2","first-page":"295","article-title":"The 7H11 medium for the cultivation of mycobacteria","volume":"98","author":"Cohn ML","year":"1968","unstructured":"Cohn ML WaggonerRF McClatchyJK. 1968. The 7H11 medium for the cultivation of mycobacteria. Am Rev Respir Dis98:295\u2013296.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12119"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0222-8"},{"key":"e_1_3_2_14_2","first-page":"59","volume-title":"Drug susceptibility in the chemotherapy of mycobacterial infections","author":"Peloquin CA","year":"1991","unstructured":"Peloquin CA . 1991. Antituberculosis drugs: pharmacokinetics, p 59\u201388. InHeifetsL (ed), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL."},{"key":"e_1_3_2_15_2","first-page":"383","volume-title":"Antimicrobial chemotherapy and vaccines","author":"Peloquin CA","year":"2005","unstructured":"Peloquin CA VernonA. 2005. Antimycobacterial agents: rifamycins for mycobacterial infections, p 383\u2013402. InYuVL EdwardsG McKinnonPS PeloquinC MorseGD (ed), Antimicrobial chemotherapy and vaccines, 2nd ed, vol II: antimicrobial agents. Esun Technologies, LLC, Pittsburgh, PA.","edition":"2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir184"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_2_18_2","first-page":"71","article-title":"Two three-month treatment regimens for pulmonary tuberculosis","volume":"51","author":"Kreis B","year":"1976","unstructured":"Kreis B PretetS BirenbaumJ GuiboutP HazemanJJ OrinE PerdrizetS WeilJ. 1976. Two three-month treatment regimens for pulmonary tuberculosis. Bull Int Union Tuberc51:71\u201375.","journal-title":"Bull Int Union Tuberc"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314210"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-06"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558209"},{"key":"e_1_3_2_23_2","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review","volume":"15","author":"Steingart KR","year":"2011","unstructured":"Steingart KR JotbladS RobskyK DeckD HopewellPC HuangD NahidP. 2011. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis15:305\u2013316.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0577"}],"updated-by":[{"DOI":"10.1128\/aac.01524-17","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000}}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00038-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00038-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:05:57Z","timestamp":1645477557000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00038-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1128\/AAC.00038-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00038-17","relation":{"correction":[{"id-type":"doi","id":"10.1128\/AAC.01524-17","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"2017-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00038-17"}}